Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: A microdialysis study in Swiss mice

British Journal of Pharmacology

Volumn 140, Issue 6, 2003, Pages 1128-1136

  David, D J P ^a,b   Bourin, M ^b   Jego, G ^a   Przybylski, C ^a   Jolliet, P ^b   Gardier, A M ^a  

^a University of Paris XI   (France)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

Antidepressants; Frontal cortex; Microdialysis; Noradrenaline; Serotonin

Indexed keywords

CITALOPRAM; NORADRENALIN; PAROXETINE; SEROTONIN; VENLAFAXINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; FRONTAL CORTEX; MALE; MICRODIALYSIS; MOUSE; NONHUMAN; NORADRENALIN BRAIN LEVEL; NORADRENALIN RELEASE; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL; SEROTONIN RELEASE; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FRONTAL LOBE; MALE; MICE; MICRODIALYSIS; NOREPINEPHRINE; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 0345688918     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705538     Document Type: Article

References (51)

1. 1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram. Naunyn-Schmiedeberg's Arch. Pharmacol., 353, 630-640.
2. ARTIGAS, F. (1995). Selective serotonin/noradrenaline reuptake inhibitors (SNRIs). CNS Drugs, 4, 79-89.
3. BARKER, E.L., KIMMEL, H.L. & BLAKELY, R.D. (1994). Chimeric human and rat serotonin transporters reveal domains involved in recognition of transporter ligands. Mol. Pharmacol., 46, 799-807.
4. BEÏQUE, J.C., LAVOIE, N., DE MONTIGNY, C. & DEBONNEL, G. (1998). Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur. J. Pharmacol., 349, 129-132.
5. BEYER, C.E., BOIKESS, S., LUO, B. & DAWSON, L.A. (2002). Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study. J. Psychopharmacol., 16, 297-304.
6. BLIER, P. (2001). Norepinephrine and selective norepinephrine reuptake inhibitors in depression and mood disorders: their pivotal roles. J. Psychiatry Neurosci., 26 (Suppl), S1-S2.
7. BLIER, P. & DE MONTIGNY, C. (1994). Current advances and trends in the treatment of depression. Trends Pharmacol. Sci., 15, 220-226.
8. BOLDEN-WATSON, C. & RICHELSON, E. (1993). Blockade by newly developed antidepressants of biogenic uptake into rat brain synaptosomes. Life Sci., 52, 1023-1029.
9. BOURIN, M., COLOMBEL, M.C., REDROBE, J.P., NIZARD, J., HASCOËT, M. & BAKER, G.B. (1998). Evaluation of efficacies of different classes of antidepressants in the forced swimming test in mice at different ages. Prog. Neuropsychopharmacol. Biol. Psychiatry, 22, 343-351.
10. BYMASTER, F.P., ZHANG, W., CARTER, P.A., SHAW, J., CHERNET, E., PHEBUS, L., WONG, D.T. & PERRY, K.W. (2002). Fluoxetine, but not other selective serotonin reuptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology, 160, 353-361.
11. 1A receptor antagonism. Neuropharmacology, 38, 1153-1163.
12. DEAKIN, B. & DURSUN, S. (2002). Optimizing antidepressant treatment: efficacy and tolerability. Int. Clin. Psychopharmacol. (Suppl 1), S13-S24.
13. DELGADO, P.L., PRICE, L.H., HENINGER, G.R. & CHARNEY, D.S. (1992). Neurochemistry of affective disorders. In: Handbook of Affective Disorders. ed. Paytkel E.S. pp. 219-253. Livingston, NY: Churchill.
14. EINARSON, T.R., ARIKIAN, S.R., CASCIANO, J. & DOYLE, J.J. (1999). Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin. Ther., 21, 296-308.
15. FRANKLIN, K.B. & PAXINOS, G. (1997). The Mouse Brain in Stereotaxic Coordinates. Toronto/San Diego: Academic Press.
16. GARDIER, A.M., DAVID, D.J., JEGO, G., PRZYBYLSKI, C., JACQUOT, C., DURIER, S., GRUWEZ, B., DOUVIER, E., BEAUVERIE, P., POISSON , N., HEN, R. & BOURIN, M (2003). Regulation of serotonin release in the frontal cortex and ventral hippocampus of homozygous mice lacking 5-HT1B receptors: in vivo microdialysis studies. J. Neurochem., 69, 2019-2025.
17. GILMOR, M.L., OWENS, M.J. & NEMEROFF, C.B. (2002). Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am. J. Psychiatry, 159, 1702-1710.
18. GOBERT, A., RIVET, J.M., CISTARELLI, L., MELON, C. & MILLAN, M.J. (1997). Alpha2-adrenoreceptor blockade markedly potentiates duloxetine-and fluoxetine-induced increases in noradrenaline, dopamine and serotonin levels in the frontal cortex of freely moving rats. J. Neurochem., 69, 2616-2619.
19. GUR, E., DREMENCOV, E., LERER, B. & NEWMAN, M.E. (1999). Venlafaxine: acute and chronic effects on 5-hydroxytryptamine levels in rat brain in vivo. Eur. J. Pharmacol., 372, 17-24.
20. HAJÓS-KORCSOK, E., MCQUADE, R. & SHARP, T. (1999). Influence of 5-HT1A receptors on central noradrenergic system activity: microdialysis studies using (±)-MDL73005EF and its enantiomers. Neuropharmacology, 38, 299-306.
21. HAJÓS-KORCSOK, E., MCTAVISH, S.F. & SHARP, T. (2000). Effect of a selective 5-hydroxytryptamine reuptake inhibitor on brain extracellular noradrenaline: microdialysis studies using paroxetine. Eur. J. Pharmacol., 407, 101-107.
22. HUGHES, Z.A. & STANFORD, S.C. (1996). Increased noradrenaline efflux induced by local infusion of fluoxetine in the rat frontal cortex. Eur. J. Pharmacol., 317, 83-90.
23. HUGHES, Z.A. & STANFORD, S.C. (1998). Evidence from microdialysis and synaptosomal studies of rat cortex for noradrenaline uptake sites with different sensitivities to SSRIs. Br. J. Pharmacol., 124, 1141-1148.
24. KOCH, S., PERRY, K.W., NELSON, D.L., CONWAY, R.G., THRELKELD, P.C. & BYMASTER, F.P. (2002). R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study. Neuropsychopharmacology, 27, 949-959.
25. LINDVALL, O., BJORKLUND, A. & DIVAC, I. (1978). Organization of catecholamine neurons projecting to the frontal cortex in the rat. Brain Res., 142, 1-24.
26. MALAGIE, I., DAVID, D.J., JOLLIET, P., HEN, R., BOURIN, M. & GARDIER, A.M. (2002). Improved efficacy of fluoxetine in increasing hippocampal 5-hydroxytryptamine outflow in 5-HT(1B) receptor knock-out mice. Eur. J. Pharmacol., 443, 99-104.
27. MALAGIE, I., DESLANDES, A. & GARDIER, A.M. (2000). Effects of acute and chronic tianeptine administration on serotonin outflow in rats: comparison with paroxetine by using in vivo microdialysis. Eur. J. Pharmacol., 403, 55-65.
28. 1B autoreceptors limit the effects of selective serotonin re-uptake inhibitors in mouse hippocampus and frontal cortex. J. Neurochem., 76, 865-871.
29. MATEO, Y., PINEDA, J., UDEGO, L. & MEANA, J.J. (1998). Somatodendritic 2-adrenoreceptors in the locus coeruleus are involved in the in vivo modulation of cortical noradrenaline release by the antidepressant desipramine. J. Neurochem., 71, 790-798.
30. MATEO, Y., RUIZ-ORTEGA, J.A., UDEGO, L. & MEANA, J.J. (2000). Inhibition of 5-hydroxytryptamine reuptake by the antidepressant citalopram in the locus coeruleus modulates the rat brain noradrenergic transmission in vivo. Neuropharmacology, 39, 2036-2043.
31. MILLAN, M.J., GOBERT, A., GIRARDON, S. & DEKEYNE, A. (1999). Citalopram elicits a discriminative stimulus in rats at dose selectively increasing extracellular levels of serotonin vs dopamine and noradrenaline. Eur. J. Pharmacol., 364, 147-150.
32. MILLAN, M.J., GOBERT, A., LEJEUNE, F., NEWMAN-TANCREDI, A., RIVET, J.M., AUCLAIR, A. & PEGLION, J.L. (2001). S33005, a novel ligand at both serotonin and norepinephrine transporters : I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J. Pharmacol. Exp. Ther., 298, 565-580.
33. MILLAN, M.J., LEJEUNE, F. & GOBERT, A. (2000). Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressants agents. J. Psychopharmacol., 14, 114-138.
34. NELSON, J.C. (1998). Augmentation strategies with serotonergic- noradrenergic combinations. J. Clin. Psychiatry, 59, 65-68.
35. NUTT, D.J. (2002). The neuropharmacology of serotonin and noradrenaline in depression. Int. Clin. Psychopharmacol., 17, S1-S12.
36. OWENS, M.J., KNIGHT, D.L. & NEMEROFF, C.B. (2000). Paroxetine binding to the rat norepinephrine transporter in vivo. Biol. Psychiatry, 47, 842-845.
37. REDROBE, J.P. & BOURIN, M. (1998a). Dose-dependant influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test. Psychopharmacology, 138, 198-206.
38. REDROBE, J.P., BOURIN, M., COLOMBEL, M.C. & BAKER, G.B. (1998b). Psychopharmacological profile of the selective serotonin reuptake inhibitor, paroxetine: implication of noradrenergic and serotonergic mechanisms. J. Psychopharmacol., 12, 155-161.
39. REDROBE, J.P., BOURIN, M., COLOMBEL, M.C. & BAKER, G.B. (1998c). Dose-dependent noradrenergic and sertonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology, 138, 1-8.
40. ROMERO, L. & ARTIGAS, F. (1997). Preferential potentiation of the effects of serotonin uptake inhibitors by 5-HT1A receptor antagonists in the dorsal raphe pathway: role of somatodendritic autoreceptors. J. Neurochem., 68, 2593-2603.
41. SÁNCHEZ, C. & HYTTEL, J. (1999). Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell. Mol. Neurobiol., 19, 467-489.
42. SEO, D.O., SHIN, C.Y., LEE, C.J., DAILEY, J.W., REITH, M.E.A., JOB, P.C. & KO, H.H. (1999). Effect of alterations in extracellular norepinephrine on adrenoreceptors: a microdialysis study in freely moving rats. Eur. J. Pharmacol., 365, 39-46.
43. SHACHAR, D., KLEIN, E., TABAK, A. & FINDBERG, J.P. (1997). Effect of single and repeated administration of fluvoxamine on noradrenaline release in rat brain. Eur. J. Pharmacol., 332, 237-243.
44. SHINKAI, K., YOSHIMURA, R., TOYOHIRA, Y., YANAGIHARA, N. & NAKAMURA, J. (2002). Inhibition mechanism of paroxetine, a selective serotonin reuptake inhibitor, on norepinephrine transporter activity. Int J. Neuropsychopharmacol., 5, S67.
45. STANFORD, S.C. (1996). Prozac: panacea or puzzle? Trends Pharmacol. Sci., 17, 150-154.
46. SZABO, S.T., DE MONTIGNY, C. & BLIER, P. (1999). Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers. Br. J. Pharmacol., 126, 568-571.
47. TALLARIDA, R.J. & MURRAY, R.B. (1987). Manual of Pharmacological Calculations with Computer Programs. New York, U.S.A.: Springer-Verlag.
48. TANDA, G., CARBONI, E., FRAU, R. & DI CHIARA, G. (1994). Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential. Psychopharmcology, 115, 285-288.
49. THASE, M.E., ENTSUAH, A.R. & RUDOLPH, R.L. (2001). Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry, 178, 234-241.
50. THOMAS, D.N., NUTT, D.J. & HOLMAN, R.B. (1998). Sertraline, a selective serotonin reuptake inhibitor modulates extracellular noradrenaline in the rat frontal cortex. J. Psychopharmacol., 12, 366-370.
51. VETULANI, J. & NALEPA, I. (2000). Antidepressants: past, present and future. Eur. J. Pharmacol., 405, 351-363.